Navigation Links
Archemix in Medical News

Alexandria Real Estate Equities Provides Update

...ical represented approximately 13% and were dominated by high-quality, leading-edge companies with blue chip venture investors, including Ambrx, Inc., archemix Corp., Fate Therapeutics, Inc., Juvaris BioTherapeutics, Inc. and TolerRx, Inc.; and the remainder of approximately 7% was comprised of traditional ...

Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

...icology studies for a number of biologic compounds, including monoclonal antibody immunoconjugates and nucleic acids at Millennium Pharmaceuticals and archemix Corp. Dr. Green will lead Taligen's development project teams for the company's two most advanced clinical candidates, TT30 and TA106, acros...

Isis Reports Financial Results and Highlights for Fiscal year 2007

...ction with Roche. * Isis licensed technology to archemix for aptamer drug applications in exchange for...s and royalties on aptamer drugs developed by archemix that incorporate Isis' proprietary chemistries or ...sis received the first milestone payment from archemix for the advancement of Archemix' aptamer drug into...
Archemix in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...velop drugs that incorporate Isis' technology resulting in financial benefits as these assets mature. Isis earned milestone payments from archemix and Alnylam because each company advanced drugs that incorporate Isis' technology. Isis co-exclusively licensed its single-stranded RNA interfe...

Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Archemix Announces Completion of Phase 1 Trial of ARC1779

... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - archemix Corp., a biotechnology company focused on discover...n as thrombotic thrombocytopenic purpura, or TTP. archemix plans to present a complete data set from this Pha...esized rather than biologically expressed. About archemix ...
Archemix in Biological Technology

Biotech Avoids Fall Out From Tough Quarter for Capital Markets

...Biotech IPOs on hold The prevailing tough economic environment also took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused o...

Biotech Drops Amid Tough Markets in February

...otech IPOs remain on hold The prevailing tough economic environment took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused o...
Other Tags
(Date:6/2/2015)... MD (PRWEB) June 02, 2015 National ... Baltimore-based creative marketing, web design and development agency, to ... , National Autism Resources’ new website ... people of all ages diagnosed with autism. The site ... and offer an array of resources, from easy to ...
(Date:6/2/2015)... LUSAKA, Zambia (PRWEB) June 02, 2015 ... agricultural businesses, today opened a new seed warehouse and ... capacity and meet farmer demand for both local and ... Africa. , “Zambia could emerge as the breadbasket ... fostered,” said Worede Woldemariam, East and South Central Africa ...
(Date:6/2/2015)... ODU , a worldwide ... solutions and cable assemblies, is announcing its highly ... US market. , ODU MINI-SNAP® is ... self- securing circular connector solution is ideal for ... significant customization such as: sensor devices, data collecting ...
(Date:6/2/2015)... WI (PRWEB) June 02, 2015 ... Worldwide Headquarters to 20800 Swenson Drive, Suite 125 ... office space provides a new base of operations ... space will accommodate future growth. , Mark Chapman, ... growth in the industry as enterprise customers adopt ...
(Date:6/2/2015)... The Non-GMO Project offers North America’s ... to rigorous best practices for GMO (genetically modified ... with the Non-GMO Project Standard - that means ... inspections and an annual audit to ensure the ... Systems is and has always been wholeheartedly committed ...
Breaking Medicine News(10 mins):Health News:National Autism Resources Launches New Website, Delivering More Products and Services 2Health News:National Autism Resources Launches New Website, Delivering More Products and Services 3Health News:Investing in Infrastructure Critical to Advancing Food Security in Zambia 2Health News:Investing in Infrastructure Critical to Advancing Food Security in Zambia 3Health News:ODU Announces ODU MINI-SNAP® - Advanced Circular Connector Solution for Highly Customizable Applications 2Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Savoury Systems International Receives Non-GMO Project Verification Continuing its Commitment to Provide Customers with Clean Label Ingredients 2
(Date:6/1/2015)... 1, 2015 According to a ... Market by Technology (Touch-based & Touchless), Application (Consumer Electronics, ... by Geography - Global Forecast to 2020", published by ... expected to reach $23.55 Billion by 2020, at a ... Browse 83 market data T ables and ...
(Date:6/1/2015)... -- According to a new market ... (Government, Military & Defense, Healthcare, Banking & Finance, ... (Face Recognition, Fingerprint Recognition, Iris Recognition, Palm Recognition, ... Function (Contact and Non-Contact) & Geography ( ... , APAC, Row) - Global Forecast to 2020", ...
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
Other Contents